Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
about
Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.Surface Plasmon Resonance Sensing of Biorecognition Interactions within the Tumor Suppressor p53 Network.Azurin interaction with the lipid raft components ganglioside GM-1 and caveolin-1 increases membrane fluidity and sensitivity to anti-cancer drugs
P2860
Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Phase I trial of p28 (NSC74510 ...... Brain Tumor Consortium Study.
@en
type
label
Phase I trial of p28 (NSC74510 ...... Brain Tumor Consortium Study.
@en
prefLabel
Phase I trial of p28 (NSC74510 ...... Brain Tumor Consortium Study.
@en
P2093
P2860
P356
P1433
P1476
Phase I trial of p28 (NSC74510 ...... Brain Tumor Consortium Study.
@en
P2093
Girish Dhall
Ian F Pollack
Ira J Dunkel
James M Boyett
Linda Bressler
Michael Pacini
Paul Graham Fisher
Rishi R Lulla
Roger J Packer
P2860
P304
P356
10.1093/NEUONC/NOW047
P577
2016-03-28T00:00:00Z